India, April 29 -- Shanghai Henlius Biotech Inc. (2696.HK) and Organon & Co. (OGN) on Wednesday, have announced that the European Commission has given the thumbs up for POHERDY, the first and only pertuzumab biosimilar approved in Europe.
POHERDY is a biosimilar to PERJETA, and it's now cleared for all the same uses as the original product, including treating HER2-positive breast cancer in both early stages and advanced cases.
The company noted that this is a big step forward in making treatment options more accessible in Europe, where breast cancer continues to be the most frequently diagnosed cancer among women.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
According to a deal made in 2022, Organ...